ImmuCell Corporation (ICCC) Fair Value 2026

ICCC · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

6.8 /10

32 fundamental signals · 7 models active

Value Trap Risk

SAFE (12/100)

Quick Summary — As of 2026-08-27, ImmuCell Corporation (ICCC) trades at $10.02, versus a $2.00 median fair value across its 7 active models — 80.0% below the current price. QOC: 6.8/10. Value Trap Risk: 12/100 (SAFE). 7/13 models active.

Key Facts

Ticker
ICCC
Price
$10.02
Quality Score
6.8/10
Value Trap Risk
12/100
Models Active
7/13
Last Updated
Strength: 7 independent models provide multi-angle coverage
Risk: Majority of models suggest overvaluation

Is ImmuCell Corporation (ICCC) Undervalued or Overvalued in 2026?

According to CirclFi’s 7-model valuation engine, ImmuCell Corporation (ICCC) appears overvalued as of : the median of 7 independent fair value estimates is $2.00, 80.0% below the current price of $10.02. Estimates range from $0.20 to $6.13. ICCC scores 6.8/10 on fundamental quality and 12/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.7% versus its own 13-model consensus, across 3,801 rated companies as of 2026-08-27. ICCC’s -80.0% gap is wider than that market norm, and the Biotechnology sector median is -64.8%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy ImmuCell Corporation Stock in 2026? →

What Fair Value Does Each Model Give ICCC?

7 Intrinsic Value Models vs. Current Price ($10.02)

Core Models (Unlocked)
Model Fair Value Upside
Ensemble · Low Conviction
 $2.00 -80.0%
Scenario · High Conviction
 $3.39 -66.2%
Intrinsic · High Conviction
 $1.22 -87.9%
Unlock the Full Matrix

Access 4 additional models including EROIC Spread, Regime Cross-Sectional, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 7 Models →

Cancel anytime · No contracts · Instant access

What Is ICCC's Fair Value Range?

Spread across 7 independent models · $0.20 to $6.13

CirclFi's 7 active models place ImmuCell Corporation (ICCC) between $0.20 and $6.13 per share, a spread of 297% of the median. The median of that range — $2.00 — is the fair value CirclFi publishes for ICCC, against a current price of $10.02.

Low · Regime CrossHigh · EROIC
$0.20median $2.00$6.13
Where the range comes from
Most bearish modelRegime Cross-Sectional$0.20
Most bullish modelEROIC Spread$6.13
Model agreement0 bullish · 7 bearishwide

A band this wide is itself the finding. When independent methods land far apart, they are reading a business whose value depends heavily on which lens you apply — volatile earnings, heavy reinvestment, or an asset base that cash-flow and asset-based methods score differently. That disagreement is information: it says the choice of method matters more than usual for ICCC. Treat the median as one reading among several and compare the individual models below before acting.

Every figure above is one model's standalone output on ICCC, not a CirclFi price target. How each model works →

What Is ImmuCell Corporation (ICCC) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, ImmuCell Corporation's intrinsic value is estimated at $2.00. Trading at its current price of $10.02, the valuation engine raises significant caution: 7 of 7 models flag downside risk, projecting a median implied return of -80.0%. Notably, EROIC sees the most upside at -38.8% (fair value: $6.13), while Regime Cross is the most conservative at -98.0% ($0.20). The spread between these extremes — +59.2% — reveals how different analytical frameworks can reach starkly different conclusions.

What Do the Models Say About ICCC?

7 of 13 models are currently active for ICCC. All 7 active models suggest the stock trades above fair value. Taken together, their median fair value for ICCC is $2.00 — the figure CirclFi publishes as this stock's fair value. See which stocks rank higher →

How Does ICCC Rank in Biotechnology?

Among 620 Biotechnology stocks, ICCC ranks #58 by Quality of Company score. CirclFi's QOC score of 6.8/10 evaluates 32 fundamental signals. A score of 6.8 indicates above-average quality.

See all Most Undervalued Biotechnology Stocks →

The Biotechnology sector introduces analytical considerations specific to life sciences company businesses. For ImmuCell Corporation, metrics like market exclusivity window provide important context that general-purpose valuation models may underweight.

Is ICCC a Value Trap?

CirclFi's Value Trap algorithm assigns ICCC a score of 12/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

7 of 13 models are active for ImmuCell Corporation. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Deep Alpha Valuation Engine, ImmuCell Corporation scores 6.8 out of 10 on our 32-signal quality assessment, a solid rating that maintains reasonable quality metrics with some areas for improvement. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.

The gap between the most bullish and bearish model spans +59.2% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every ICCC valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across ICCC's 7 active models, average confidence is 39%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy ImmuCell Corporation Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

FDMT4D Molecular Therapeutics, Inc.QOC 6.8OCGNOcugen, Inc.QOC 6.8PLXProtalix BioTherapeutics, Inc.QOC 6.9TNGXTango Therapeutics, Inc.QOC 6.8LCTXLineage Cell Therapeutics, Inc.QOC 6.9QTTBQ32 Bio Inc.QOC 6.8ASBPAspire Biopharma Holdings, Inc.QOC 5.5KPTIKaryopharm Therapeutics Inc.QOC 4.8NGENNervGen Pharma Corp.QOC 4.1EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: FDMT · OCGN · PLX · TNGX · LCTX · QTTB · ASBP · KPTI · NGEN · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to ICCC?

6 companies across all industries closest to ICCC’s Quality of Company score of 6.8/10.

CIZNCitizens Holding CompanyQOC 6.8SMRNuScale Power CorporationQOC 6.8OIO-I Glass, Inc.QOC 6.8BHICBioScience Health Innovations IQOC 6.8ICHRIchor Holdings, Ltd.QOC 6.8NVDANVIDIA CorporationQOC 10.0

Read investment analysis: CIZN · SMR · OI · BHIC · ICHR · NVDA

Where Does ICCC Sit in CirclFi's Biotechnology Rankings?

ICCC is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About ImmuCell Corporation’s Valuation?

What is ImmuCell Corporation's intrinsic value in 2026?

CirclFi puts ImmuCell Corporation (ICCC)'s intrinsic value at $2.00 — the median of 7 independent model estimates as of 2026-08-27, ranging from $0.20 to $6.13. The Quality of Company score is 6.8/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is ICCC overvalued or undervalued right now?

At $10.02, 0 of 7 active models suggest ICCC may be undervalued, while 7 indicate potential overvaluation. The median of all 7 fair value estimates is $2.00, 80.0% below the current price of $10.02 — a consensus view that ICCC is overvalued. The assessment depends on which methodology best fits ImmuCell Corporation's business model in Biotechnology.

What does a Quality of Company score of 6.8 mean for ICCC?

ImmuCell Corporation's QOC of 6.8/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on ICCC?

CirclFi analyzes ICCC with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 7 of 13 are active for this stock. Read the full methodology →

Which valuation models are most bullish and most bearish on ICCC?

Of the 7 models currently active on ICCC, EROIC Spread is the most bullish at $6.13 per share, and Regime Cross-Sectional is the most bearish at $0.20. CirclFi's published fair value for ICCC is the median of that range, $2.00, not either extreme. The gap between the two ends equals 297% of the median — a wide spread, meaning the methods genuinely disagree and the median should carry less weight. Browse stocks by value-trap risk →

Is ICCC a value trap in 2026?

ImmuCell Corporation's Value Trap score is 12/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap.

Cite this analysis — “According to CirclFi’s 7-model valuation engine, ImmuCell Corporation (ICCC) has a median fair value of $2.00 — 80.0% below the current price of $10.02 — as of 2026-08-27.” Source: circlfi.com/stock/ICCC/ · Methodology
Primary sources for this ICCC valuation
  • Financial statements: ImmuCell Corporation 10-K and 10-Q filings on SEC EDGAR (CIK 0000811641) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for ICCC as of ; valuations recomputed .

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 7 mathematical frameworks give you clarity on ICCC.

Unlock All 7 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access

4 models hidden for ICCC Unlock All 7 — $39/mo